Entering text into the input field will update the search result below

Keytruda + Lenvima combo shows positive effect in Phase 1b/2 study in three tumor types

Nov. 09, 2018 7:12 AM ETMerck & Co., Inc. (MRK) StockBy: Douglas W. House, SA News Editor
  • Preliminary data from a Phase 1b/2 clinical trial evaluating Merck's (NYSE:MRK) Keytruda (pembrolizumab) plus Eisai's (OTCPK:ESALY) Lenvima (lenvatinib) in patients with metastatic non-small cell lung cancer (NSCLC), metastatic melanoma and metastatic urothelial carcinoma showed a treatment effect. The results are being presented at the SITC annual meeting in Washington, DC.
  • The trial, Study 111/KEYNOTE-146, is a single-arm, open-label basket study. Participants were not selected based on PD-L1 expression. The primary endpoint of the first phase was maximum tolerated dose. The primary endpoint of the second phase is objective response rate (ORR) at week 24.
  • At data cutoff, the ORR in NSCLC patients who had received up to two prior lines of therapies was 33.3% (n=7/21). The ORR in melanoma patients who had received up to two prior treatments was 47.6% (n=10/21). The ORR in urothelial cancer patients who had received up to two prior treatments was 25.0% (n=5/20).
  • Pembrolizumab is a PD-1 inhibitor and lenvatinib is a kinase inhibitor.
  • The study is ongoing.

Recommended For You

More Trending News

About MRK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRK--
Merck & Co., Inc.